Susquehanna Fundamental Investments, LLC Humanigen, Inc Transaction History

Susquehanna Fundamental Investments, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	BUY	$3.66 - $8.22 $159,484 - $358,186	43,575 New	43,575 $162,000
Q3 2021 Nov 15, 2021	SELL	$5.93 - $17.83 $204,555 - $615,045	-34,495 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$13.54 - $22.74 $47,484 - $79,749	-3,507 Reduced 9.23%	34,495 $600,000
Q1 2021 May 17, 2021	BUY	$12.91 - $23.83 $6,455 - $11,915	500 Added 1.33%	38,002 $726,000
Q4 2020 Feb 16, 2021	BUY	$7.97 - $21.66 $298,890 - $812,293	37,502 New	37,502 $656,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.